A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
Public ClinicalTrials.gov record NCT02935634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Study identification
- NCT ID
- NCT02935634
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Relatlimab Biological
- BMS-986205 Biological
- Rucaparib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2016
- Primary completion
- May 10, 2022
- Completion
- May 10, 2022
- Last update posted
- Jun 8, 2023
2016 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Local Institution - 0020 | Duarte | California | 91010-3000 | — |
| University Of Colorado | Aurora | Colorado | 80045 | — |
| Local Institution - 0032 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0036 | Washington D.C. | District of Columbia | 20007 | — |
| UF Health Medical Oncology - Davis Cancer Pavilion | Gainesville | Florida | 32610 | — |
| Local Institution - 0038 | Jacksonville | Florida | 32224 | — |
| Local Institution - 0006 | Baltimore | Maryland | 21224 | — |
| Local Institution - 0017 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0003 | St Louis | Missouri | 63110 | — |
| Local Institution - 0001 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0007 | New York | New York | 10065 | — |
| Local Institution - 0002 | Portland | Oregon | 97225 | — |
| Local Institution - 0005 | Philadelphia | Pennsylvania | 19111 | — |
| UPMC | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0004 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02935634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2023 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02935634 live on ClinicalTrials.gov.